NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Capricor Therapeutics, Inc. (CAPR) Stock Analysis

Capricor Therapeutics, Inc. (CAPR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CAPR

$9.40

+$0.12 (+1.29%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CAPR with… →

CAPR Key Statistics

As of Sep 4, 2026
Trading
Open
$9.40
Previous Close
$9.28
Day's Range
9.26–9.81
52-Week Range
2.96–40.37
Volume
2.54M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.72
Valuation
Market Cap
$546.51M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.38
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.45
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$105.04M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
58.14M
1-Year Return
+58.25%
Dividend and dates
Earnings Date
November 10, 2026
Avg Volume
6.18M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CAPR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−67.43%
2025+109.13%
2024+182.21%
2023+26.68%
2022+31.74%
2021−14.58%
2020+167.97%
2019−68.78%
2018−74.05%
2017−40.60%
2016 (partial year)−32.49%

As of September 4, 2026.

CAPR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$105.04M—
2024$22.27M−$40.47M−181.7%
2023$25.18M−$22.29M−88.5%
2022$2.55M−$29.02M−1137.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$108.14M−$105.04M—
2024$22.27M—−$42.56M−$40.47M−181.7%
2023$25.18M—−$24.08M−$22.29M−88.5%
2022$2.55M—−$29.70M−$29.02M−1137.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CAPR Valuation vs Biotechnology Median

Median of 656 stocks
MetricCAPRBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Capricor Therapeutics, Inc. (CAPR) is capitalised at $546.51M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 231 employees.

CAPR last closed at $9.40 on September 4, 2026. That is +$0.12 (+1.29%) against the previous close. The 52-week range on file runs from $2.96 to $40.37. The latest close sits 217.57% above that 52-week low.

Financial Health

In fiscal 2025, Capricor Therapeutics, Inc. reported revenue of $0.00. That is −100.00% against the prior fiscal year, when revenue was $22.27M. The same year closed with a net loss of $105.04M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −2.45.

Across the 4 fiscal years on file, revenue moves from $2.55M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.38.

Over the trailing twelve months the price has returned +58.25%. Measured over 10 years, that is −13.04% a year compounded. The reported beta is 0.72. Annualized volatility over the trailing 10 years is 182.61%.

Growth & Income

The record shows no dividend for CAPR.

2026 is still running; the price is −67.43% year to date. Across the complete calendar years on file, 2024 returned +182.21% and 2018 returned −74.05%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Capricor Therapeutics, Inc. (CAPR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Capricor Therapeutics, Inc. CAPR $546.51M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Capricor Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Visit website →